4 HealthTech Stocks Trending Now SQZ stock, BMRN stock, RIGL stock, AVXL stock
Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at finmarketnews.com, will continue to monitor these healthtech companies to see if the momentum continues. FinMarketNews.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent SQZ Stock Price: $1.55
Summary: SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Emily Bodnar analyst at H.C. Wainwright reiterates coverage on SQZ Biotechnologies (SQZ) stock in the energy sector with a Hold rating and has set SQZ's stock price target at n/a.
TipRanks.com reports that SQZ Biotechnologies currently has 5 analysts offering 12-month price targets on SQZ and the consensus is a Moderate Buy rating with an average stock price target of $15.75. The most recent SQZ stock price we have is $1.55 and we are not making any SQZ forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for SQZ over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SQZ. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SQZ, please click here >>
BioMarin Pharmaceutical, BMRN
Recent BMRN Stock Price: $105.56
Summary: BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
Joshua Schimmer analyst at Evercore ISI reiterates coverage on BioMarin Pharmaceutical (BMRN) stock in the energy sector with a Buy rating and has set BMRN's stock price target at $ 130.
TipRanks.com reports that BioMarin Pharmaceutical currently has n/a analysts offering 12-month price targets on BMRN and the consensus is a Strong Buy rating with an average stock price target of n/a. The most recent BMRN stock price we have is $105.56 and we are not making any BMRN forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for BMRN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BMRN. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BMRN, please click here >>
Rigel, RIGL
Recent RIGL Stock Price: $0.834
Summary: Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.
Yigal Nochomovitz analyst at Citigroup reiterates coverage on Rigel (RIGL) stock in the energy sector with a Buy rating and has set RIGL's stock price target at $ 2.
TipRanks.com reports that Rigel currently has 4 analysts offering 12-month price targets on RIGL and the consensus is a Strong Buy rating with an average stock price target of $5.25. The most recent RIGL stock price we have is $0.834 and we are not making any RIGL forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for RIGL over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RIGL. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on RIGL, please click here >>
Anavex Life Sciences, AVXL
Recent AVXL Stock Price: $12.05
Summary: ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways.
Caroline Palomeque analyst at Berenberg Bank reiterates coverage on Anavex Life Sciences (AVXL) stock in the energy sector with a Buy rating and has set AVXL's stock price target at $ 40.
TipRanks.com reports that Anavex Life Sciences currently has 4 analysts offering 12-month price targets on AVXL and the consensus is a Strong Buy rating with an average stock price target of $49.25. The most recent AVXL stock price we have is $12.05 and we are not making any AVXL forecasts at this time.
In addition, TradingView issued a n/a (possibly response change) rating for AVXL over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on AVXL. finmarketnews.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AVXL, please click here >>
The editors at finmarketnews.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinMarketNews.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinMarketNews.com.
==============================================================================